Literature DB >> 2571988

Profile of in vitro binding affinities of neuroleptics at different rat brain receptors: cluster analysis comparison with pharmacological and clinical profiles.

R Testa1, G Abbiati, R Ceserani, G Restelli, A Vanasia, D Barone, M Gobbi, T Mennini.   

Abstract

A series of 21 neuroleptics with different chemical structures (phenothiazines, thioxanthenes, dibenzodiazepines, butyrophenones, benzamides, etc.) was examined for their in vitro interactions with 12 neurotransmitter binding sites in the rat brain (alpha- and beta-noradrenergic, dopaminergic, muscarinic, serotoninergic, histaminic, and opioid receptors, calcium channels, and serotonin uptake binding sites). The biochemical profile obtained from the binding data was compared with reported pharmacological and clinical profiles for this class of compounds by cluster analysis. Cluster analysis on binding data classified the compounds in three main subgroups: benzamides, compounds with an affinity mainly for DA2 and 5-HT2 receptors and inactive at muscarinic receptors, and compounds with a high affinity for alpha 1-adrenergic receptors and muscarinic receptors. The main subgroups resulting from cluster analysis of previously published pharmacological and clinical data for neuroleptics contain compounds common to the present study, with some correlations. The results extend previous observations that a complete binding profile corresponds to the pharmacological and clinical profile of this class of compounds.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2571988     DOI: 10.1023/a:1015997213587

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  24 in total

1.  Comparison of the in-vitro receptor selectivity of substituted benzamide drugs for brain neurotransmitter receptors.

Authors:  J K Chivers; W Gommeren; J E Leysen; P Jenner; C D Marsden
Journal:  J Pharm Pharmacol       Date:  1988-06       Impact factor: 3.765

2.  Neuroleptic drug interactions with norepinephrine alpha receptor binding sites in rat brain.

Authors:  S J Peroutka; D C U'Prichard; D A Greenberg; S H Snyder
Journal:  Neuropharmacology       Date:  1977-09       Impact factor: 5.250

Review 3.  The use of multivariate statistics in industrial pharmacology.

Authors:  P J Lewi
Journal:  Pharmacol Ther B       Date:  1978

4.  Antagonism by neuroleptics of serotonin 5-HT1A and 5-HT2 receptors of normal human brain in vitro.

Authors:  T J Wander; A Nelson; H Okazaki; E Richelson
Journal:  Eur J Pharmacol       Date:  1987-11-10       Impact factor: 4.432

5.  Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves.

Authors:  A DeLean; P J Munson; D Rodbard
Journal:  Am J Physiol       Date:  1978-08

6.  Binding characteristics of 3H-prazosin to rat brain alpha-adrenergic receptors.

Authors:  P Greengrass; R Bremner
Journal:  Eur J Pharmacol       Date:  1979-05-01       Impact factor: 4.432

7.  Histamine H1 receptors identified in mammalian brain membranes with [3H]mepyramine.

Authors:  V T Tran; R S Chang; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1978-12       Impact factor: 11.205

8.  Characterization of the binding of 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum.

Authors:  W Billard; V Ruperto; G Crosby; L C Iorio; A Barnett
Journal:  Life Sci       Date:  1984-10-29       Impact factor: 5.037

9.  Muscarinic cholinergic binding in rat brain.

Authors:  H I Yamamura; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1974-05       Impact factor: 11.205

10.  Characterization of binding of the Ca++ channel antagonist, [3H]nitrendipine, to guinea-pig ileal smooth muscle.

Authors:  G T Bolger; P Gengo; R Klockowski; E Luchowski; H Siegel; R A Janis; A M Triggle; D J Triggle
Journal:  J Pharmacol Exp Ther       Date:  1983-05       Impact factor: 4.030

View more
  4 in total

1.  Dopamine receptor blockade attenuates the general incentive motivational effects of noncontingently delivered rewards and reward-paired cues without affecting their ability to bias action selection.

Authors:  Sean B Ostlund; Nigel T Maidment
Journal:  Neuropsychopharmacology       Date:  2011-09-14       Impact factor: 7.853

2.  Chlorpromazine inhibits nitric oxide-mediated increase in intracellular cGMP in a mouse teratocarcinoma cell line.

Authors:  M Fratelli; R Delgado; M Zinetti; G Galli; Y Rolland; P Ghezzi
Journal:  Inflamm Res       Date:  1995-07       Impact factor: 4.575

3.  Chlorpromazine inhibits tumour necrosis factor synthesis and cytotoxicity in vitro.

Authors:  M Zinetti; G Galli; M T Demitri; G Fantuzzi; M Minto; P Ghezzi; R Alzani; E Cozzi; M Fratelli
Journal:  Immunology       Date:  1995-11       Impact factor: 7.397

Review 4.  KV11.1, NaV1.5, and CaV1.2 Transporter Proteins as Antitarget for Drug Cardiotoxicity.

Authors:  Magdalena Kowalska; Jacek Nowaczyk; Alicja Nowaczyk
Journal:  Int J Mol Sci       Date:  2020-10-30       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.